Jean-Charles Soria.

Lecia V. Sequist, M .D., M.P.H., Jean-Charles Soria, M.D., Ph.D., Jonathan W. Goldman, M.D., Heather A. Wakelee, M.D., Shirish M. Gadgeel, M.D., Andrea Varga, M.D., Vassiliki Papadimitrakopoulou, M.D., Benjamin J. Solomon, M.B., B.S., Ph.D., Geoffrey R. Oxnard, M.D., Rafal Dziadziuszko, M.D., Ph.D., Dara L. Aisner, M.D., Ph.D., Robert C. Doebele, M.D., Ph.D., Cathy Galasso, R.N., O.C.N., C.C.R.P., Edward B. Garon, M.D., Rebecca S. Heist, M.D., M.P.H., Jennifer Logan, N.P., Joel W. Neal, M.D., Ph.D., Melody A. Mendenhall, M.P.-C., Suzanne Nichols, R.N., Zofia Piotrowska, M.D., Antoinette J.

Sensitivity analyses involved the usage of a logistic-regression method for multiple imputation,22 as applied in SAS software program . The imputation model included the variables in the primary models plus the variables utilized to define the subgroups. Imputations were done twice for every comparison: the first, individually in each treatment group, and the second, in the combined treatment groups. Results Recruitment in the ACCORD trial began with a vanguard phase in January 2001; in February 2003 the main trial began. The ACCORD Eye research began in October 2003, by February 2006 with 3537 participants enrolled. Of the, 65 had been later found to be ineligible after recruitment, leaving 3472 qualified to receive follow-up.